Related Experiment Video

Updated: Jul 9, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Rationale for new drugs targeting the tissue microenvironment in patients with HCC

S Antonaci1, G Giannelli

  • 1Department of Internal Medicine, Immunology, and Infectious Diseases, Section of Internal Medicine, University of Bari Medical School, Bari, Italy.

Current Pharmaceutical Design
|November 30, 2007
PubMed

Insights

Targeting the liver microenvironment shows promise for treating hepatocellular carcinoma (HCC). Biological therapies offer new avenues beyond destructive approaches for this challenging cancer.

Area of Science:

  • Hepatocellular Carcinoma Research
  • Cancer Biology
  • Tumor Microenvironment

Background:

  • Hepatocellular carcinoma (HCC) treatment is limited by its development on cirrhotic livers, restricting conventional chemotherapy.
  • Current HCC therapies primarily focus on tumor destruction, lacking consolidation or curative options.
  • The tumor microenvironment is increasingly recognized as a critical factor in HCC progression and treatment response.

Purpose of the Study:

  • To review the role and rationale of biological drugs targeting the tumor microenvironment in HCC.
  • To discuss new experimental advances in targeting the liver microenvironment for HCC therapy.
  • To bridge the gap between experimental findings and clinical outcomes for biological therapies in HCC.

Main Methods:

  • Literature review of studies on hepatocellular carcinoma (HCC) mechanisms and microenvironment.
  • Analysis of biological therapies, including epithelial growth factor receptor (EGFR) inhibitors.
  • Evaluation of experimental data and clinical trial results for HCC treatments.

Main Results:

  • The tumor microenvironment is a promising target for novel hepatocellular carcinoma (HCC) therapies.
  • Biological drugs targeting the microenvironment show potential, despite current clinical discrepancies.
  • Identifying molecular pathways is key to enhancing drug effectiveness against HCC.

Conclusions:

  • Targeting the hepatocellular carcinoma (HCC) microenvironment offers a promising strategy for improving treatment outcomes.
  • Biological therapies hold potential for HCC, necessitating further research into molecular pathways and clinical efficacy.
  • Future HCC treatments may leverage the tumor microenvironment to overcome limitations of current approaches.

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

A Biomimetic Model for Liver Cancer to Study Tumor-Stroma Interactions in a 3D Environment with Tunable Bio-Physical Properties08:40

A Biomimetic Model for Liver Cancer to Study Tumor-Stroma Interactions in a 3D Environment with Tunable Bio-Physical Properties

Published on: August 7, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...